0
Clinical Trial ? AI-assigned paper type based on the abstract. Classification may not be perfect — flag errors using the feedback button. Tier 1 ? Systematic review or meta-analysis. Synthesizes findings across many studies. Strongest evidence. Sign in to save

Artificial engineering of the protein corona at bio-nano interfaces for improved cancer-targeted nanotherapy

Journal of Controlled Release 2022 67 citations ? Citation count from OpenAlex, updated daily. May differ slightly from the publisher's own count. Score: 65 ? 0–100 AI score estimating relevance to the microplastics field. Papers below 30 are filtered from public browse.
Zehra Edis, Mojtaba Falahati, Mojtaba Falahati, Suliman Khan, Zehra Edis, Majid Sharifi, Samir Haj Bloukh, Samir Haj Bloukh, Majid Sharifi, Timo L.M. ten Hagen, Jason P. Gleghorn, Mohammad Mahdi Nejadi Babadaei, Mohammad Mahdi Nejadi Babadaei, Samir Haj Bloukh, Timo L.M. ten Hagen, Zehra Edis, Mohammadreza Amin, Mohammadreza Amin, Qian Bai, Timo L.M. ten Hagen, Mojtaba Falahati, William C. Cho

Summary

Researchers reviewed how engineering the protein corona — the layer of proteins that coats nanoparticles in biological fluids — through modifications like PEGylation and protein pre-coating can improve nanoparticle targeting for cancer drug delivery by controlling how immune cells recognize and clear the particles.

Nanoparticles (NPs) have been used in numerous applications as anticancer, antibacterial and antioxidant agents. Artificial engineering of protein interactions with NPs in biological systems is crucial to develop potential NPs for drug delivery and cancer nanotherapy. The protein corona (PC) on the NP surface, displays an interface between biomacromolecules and NPs, governing their pharmacokinetics and pharmacodynamics. Upon interaction of proteins with the NPs, their surface features are modified and they can easily be removed from the circulation by the mononuclear phagocytic system (MPS). PC properties heavily depend on the biological microenvironment and NP physicochemical parameters. Based on this context, we have surveyed different approaches that have been used for artificial engineering of the PC composition on NP surfaces. We discussed the effects of NP size, shape, surface modifications (PEGylation, self-peptide, other polymers), and protein pre-coating on the PC properties. Additionally, other factors including protein source and structure, intravenous injection and the subsequent shear flow, plasma protein gradients, temperature and local heat transfer, and washing media were considered in the context of their effects on the PC properties and overall target cellular effects. Moreover, the effects of NP-PC complexes on cancer cells based on cellular interactions, organization of intracellular PC (IPC), targeted drug delivery (TDD) and regulation of burst drug release profile of nanoplatforms, enhanced biocompatibility, and clinical applications were discussed followed by challenges and future perspective of the field. In conclusion, this paper can provide useful information to manipulate PC properties on the NP surface, thus trying to provide a literature survey to shorten their shipping from preclinical to clinical trials and to lay the basis for a personalized PC.

Sign in to start a discussion.

Share this paper